Company Overview
Snapshot
Founded in January 2014 by Arik Hanannel and Ron Aginsky, FUSMobile operates with 11–50 employees. The company has secured funding across one round from OrbiMed. FUSMobile's Neurolyser XR focused ultrasound device has completed its first-in-human study with positive results and is preparing for pivotal clinical trials.
Business overview
FUSMobile is a Health Tech & Life Sciences company focused on developing non-invasive solutions for chronic pain conditions. The company's core product, Neurolyser, is a focused ultrasound treatment platform designed to thermally ablate nerves, offering a non-invasive alternative for conditions such as chronic lower back pain, knee and hip arthritis, sacroiliitis, and bone metastases. FUSMobile aims to improve patient experience and clinical outcomes while reducing healthcare costs for providers and payers, serving the healthcare industry with its medical device technology.
Strategic signal
In October 2017, FUSMobile initiated a clinical trial in Canada for facet arthritis low back pain, signaling the company's progression towards regulatory approval and market entry for its Neurolyser technology. This move indicates a strategic focus on validating the efficacy of its non-invasive focused ultrasound treatment for chronic pain, which could significantly impact the interventional pain management market.
Log in to access full profile ›Company Intelligence Q&A
- What is FUSMobile's primary focus?
- FUSMobile is dedicated to advancing non-invasive solutions for chronic painful conditions to enhance patient experience, improve clinical outcomes, and reduce healthcare costs for providers and payers.
- When was FUSMobile founded and by whom?
- FUSMobile was founded in January 2014 by Arik Hanannel and Ron Aginsky.
- What is the Neurolyser XR device?
- The Neurolyser XR is FUSMobile's focused ultrasound treatment platform designed to relieve suffering from various common conditions, including chronic lower back pain, knee and hip arthritis, sacroiliitis, and bone metastases, by thermally ablating nerves non-invasively.
- Has FUSMobile's Neurolyser XR undergone clinical studies?
- Yes, FUSMobile's Neurolyser XR focused ultrasound device has completed its first-in-human study with excellent results and is preparing to enter pivotal clinical trials for North American regulatory approval for facet joint arthritis.